Let-7d and miR-185 Impede Epithelial-Mesenchymal Transition by Downregulating Rab25 in Breast Cancer.
Let-7d
Rab25
breast cancer
epithelial-mesenchymal transition
miR-185
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Jan 2021
01 Jan 2021
Historique:
received:
21
09
2020
entrez:
28
1
2021
pubmed:
29
1
2021
medline:
21
9
2021
Statut:
epublish
Résumé
MicroRNAs (miRNAs) expression has deregulated in several cancer types including breast cancer (BC). The present study aims at investigating the role, mechanism, clinical value of let-7d and miR-185 in BC, and the possible correlation these miRNAs with Rab25. Tumor samples as well adjacent normal tissues (ANT) were acquired from fresh surgical specimens from 110 patients and the expression levels of let-7d, miR-185, Rab25, and snail were evaluated using real-time PCR. The immunohistochemical (IHC) process and western blot were done to detect the level of Rab25 and Snail protein expression in BC samples. By comparing miRNAs expression profiles in clinical tissues of 110 patients using real-time PCR, let-7d, and miR-185 expression were dramatically downregulated in BC tissues (P < 0.05). Tumor size, stage, and lymph node metastasis were significantly related to miRNAs expression. Based on qRT-PCR and bioinformatics database analyses, we also recognized Rab25 as a possible target of miR-185 and let-7d. Rab25 expression was enhanced in BC cells and associated inversely with the expression level of mentioned miRNAs. qRT-PCR, immunohistochemistry, and western blot studies verified that Rab25 upregulation increased the levels of the snail, that key transcription factor of epithelial-mesenchymal transition (EMT). These findings demonstrated that let-7d and miR-185 inhibited EMT by targeting Rab25 expression in BC. Therefore, targeting the let-7d and miR-185/Rab25 interaction may offer new therapeutic opportunities for treating BC patients.<br />.
Identifiants
pubmed: 33507713
doi: 10.31557/APJCP.2021.22.1.305
pmc: PMC8184182
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN185 microRNA, human
0
MicroRNAs
0
Rab25 protein, human
0
mirnlet7 microRNA, human
0
rab GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
305-313Références
Mol Carcinog. 2016 Dec;55(12):1990-2000
pubmed: 26618772
Drug Res (Stuttg). 2017 Sep;67(9):509-514
pubmed: 28628924
Breast Cancer Res Treat. 2015 Apr;150(3):501-9
pubmed: 25794773
Artif Cells Nanomed Biotechnol. 2017 Sep;45(6):1-6
pubmed: 27684298
Tumour Biol. 2017 May;39(5):1010428317695032
pubmed: 28468581
Am J Cancer Res. 2015 Aug 15;5(9):2719-29
pubmed: 26609479
J Cell Physiol. 2019 Nov;234(11):19199-19211
pubmed: 31026062
Biomed Pharmacother. 2017 Feb;86:426-433
pubmed: 28012397
J Cell Biochem. 2018 Nov 2;:
pubmed: 30390327
J Transl Med. 2014 Jan 21;12:17
pubmed: 24447584
Thorac Cancer. 2018 Apr;9(4):472-479
pubmed: 29524309
Biomed Pharmacother. 2018 Jun;102:608-617
pubmed: 29602128
Exp Cell Res. 2017 Aug 15;357(2):192-201
pubmed: 28527695
Int J Mol Sci. 2016 Dec 12;17(12):
pubmed: 27973455
Onco Targets Ther. 2016 May 04;9:2639-48
pubmed: 27226726
Diagn Cytopathol. 2016 May;44(5):442-9
pubmed: 26865409
Annu Rev Pathol. 2018 Jan 24;13:395-412
pubmed: 29414248
Iran J Basic Med Sci. 2018 Nov;21(11):1167-1173
pubmed: 30483391
Oncotarget. 2016 Jun 28;7(26):40252-40265
pubmed: 27259233
Tumour Biol. 2017 Feb;39(2):1010428317691682
pubmed: 28222665
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Oncol Rep. 2017 Nov;38(5):3144-3152
pubmed: 29048659
Artif Cells Nanomed Biotechnol. 2016 Dec;44(8):1972-1978
pubmed: 26772615
Cell Physiol Biochem. 2018;47(5):2126-2135
pubmed: 29975923
Oncol Rep. 2018 Jun;39(6):3086-3094
pubmed: 29658612
DNA Cell Biol. 2016 Sep;35(9):521-9
pubmed: 27303812
Dev Cell. 2018 Jun 18;45(6):681-695.e4
pubmed: 29920274
Drug Res (Stuttg). 2018 Dec;68(12):710-716
pubmed: 29920623
Biochem Biophys Res Commun. 2016 Oct 28;479(4):676-682
pubmed: 27693697
Cell Death Dis. 2013 Jun 27;4:e699
pubmed: 23807228
Nat Med. 2004 Nov;10(11):1251-6
pubmed: 15502842
Mol Cancer. 2011 May 06;10:50
pubmed: 21548940
Artif Cells Nanomed Biotechnol. 2018;46(sup2):241-247
pubmed: 29569937
Mol Cancer. 2014 Sep 06;13:206
pubmed: 25193015
Anticancer Agents Med Chem. 2017;17(5):662-673
pubmed: 27604683
Int J Oncol. 2018 Aug;53(2):781-790
pubmed: 29845224
Iran J Cancer Prev. 2016 Aug 16;9(4):e4190
pubmed: 27761206
Nature. 2016 Dec 22;540(7634):552-558
pubmed: 27974799
Genet Mol Res. 2017 Aug 17;16(3):
pubmed: 28829888
Mater Sci Eng C Mater Biol Appl. 2019 Nov;104:110007
pubmed: 31500008
Artif Cells Nanomed Biotechnol. 2018 Jun;46(4):819-830
pubmed: 28695751
J Cell Physiol. 2019 Aug;234(8):12341-12352
pubmed: 30609026
Asian Pac J Cancer Prev. 2015;16(18):8259-63
pubmed: 26745070
Exp Ther Med. 2014 Dec;8(6):1879-1883
pubmed: 25371748
Curr Cancer Drug Targets. 2018;18(3):266-277
pubmed: 28669338
Int J Mol Cell Med. 2019 Spring;8(2):118-129
pubmed: 32215263
Int J Biochem Cell Biol. 2018 Apr;97:43-51
pubmed: 29425833
Curr Mol Med. 2019;20(1):13-35
pubmed: 31573884